---
document_datetime: 2024-04-16 17:03:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/goresp-digihaler-previously-budesonide-formoterol-teva-pharma-bv-epar-all-authorised-presentations_en.pdf
document_name: goresp-digihaler-previously-budesonide-formoterol-teva-pharma-bv-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.06539
conversion_datetime: 2025-12-18 21:12:31.729741
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) Name   | Strength        | Pharmaceutical form   | Route of administration   | Immediate Packaging   | Pack size                |
|------------------|-------------------|-----------------|-----------------------|---------------------------|-----------------------|--------------------------|
| EU/1/19/1403/001 | GoResp Digihaler  | 160 μg / 4.5 μg | Inhalation powder     | Inhalation use            | inhaler               | 1 inhaler (180 doses)    |
| EU/1/19/1403/002 | GoResp Digihaler  | 160 μg / 4.5 μg |                       | Inhalation use            | inhaler               | 2 inhalers (2x180 doses) |
| EU/1/19/1403/003 | GoResp Digihaler  | 160 μg / 4.5 μg | Inhalation powder     | Inhalation use            | inhaler               | 3 inhalers (3x180 doses) |
| EU/1/19/1403/004 | GoResp Digihaler  | 320 μg / 9 μg   | Inhalation powder     | Inhalation use            | inhaler               | 1 inhaler (90 doses)     |
| EU/1/19/1403/005 | GoResp Digihaler  | 320 μg / 9 μg   | Inhalation powder     | Inhalation use            | inhaler               | 2 inhalers (2x90 doses)  |
| EU/1/19/1403/006 | GoResp Digihaler  | 320 μg / 9 μg   | Inhalation powder     | Inhalation use            | inhaler               | 3 inhalers (3x90 doses)  |